These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
6. [Similarity of biotechnology-derived drugs: regulatory framework and specificity]. Prugnaud JL Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566 [TBL] [Abstract][Full Text] [Related]
9. An audience with Thomas Lönngren. Interview by Asher Mullard. Lönngren T Nat Rev Drug Discov; 2010 Dec; 9(12):912. PubMed ID: 21119726 [No Abstract] [Full Text] [Related]
10. SuperGenerics: a better alternative for biogenerics. Charles SA Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591 [No Abstract] [Full Text] [Related]
11. Patent infringement. Generic HIV drugmaker's patent claim is time-barred. AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916 [No Abstract] [Full Text] [Related]
12. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
13. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
14. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
15. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
16. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
17. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
18. The generic drug approval process. Rheinstein PH Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762 [No Abstract] [Full Text] [Related]
19. Lessons from Eprex for biogeneric firms. Louët S Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539 [No Abstract] [Full Text] [Related]
20. Amendments to the Canadian Patent Act to address drug access: is help on the way? Penner MD; Narayanan P Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751 [No Abstract] [Full Text] [Related] [Next] [New Search]